Congressman Stephen Lynch (D-Mass.) Tested positive for COVID-19, but remains asymptomatic after receiving the second dose of the coronavirus vaccine, his office said on Friday.
Why it matters: Lynch’s case emphasizes the importance of maintaining social distance and wearing a face mask, even after vaccination.
Support safe, smart and sensible journalism. Sign up for Axios Newsletters here.
What they are saying: Lynch received a positive test result on Friday “after a member of the Congressman’s Boston office staff tested positive earlier in the week,” Lynch’s spokeswoman Molly Rose Tarpey said in a statement, according to the Boston Globe.
-
“Congressman Lynch received the second dose of the Pfizer vaccine and subsequently received a negative COVID-19 test before participating in President Biden’s inauguration,” she added.
-
Lynch “remains asymptomatic and feels good”, but will remain “quarantined and will vote by proxy in Congress in the coming weeks”.
-
It is not clear when Lynch received each dose of the vaccine.
-
Lynch’s office did not immediately respond to Axios’ request for comment.
The big picture: Pfizer-BioNTech and Moderna, the companies that developed the two vaccines authorized in the U.S., say their vaccines are about 95% effective in preventing disease after receiving the second dose of their respective vaccines.
-
“It usually takes a few weeks for the body to develop immunity (protection against the virus that causes COVID-19) after vaccination,” notes the Center for Disease Control and Prevention.
-
“This means that it is possible that a person could be infected with the virus that causes COVID-19 before or shortly after vaccination and still become ill. This is because the vaccine did not have enough time to provide protection,” adds the CDC.
-
It is also unclear how effective the vaccine is against infection and transmission, but researchers say it should prevent people from getting sick.
Go deeper: We are selling the short coronavirus vaccine
Be smart: Sign up for free for America’s most influential newsletter.